Answers are grounded in this paper and cite their sources.
Introduction: Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. This neuromuscular disease marked by repetitive intermittent skeletal muscle weakness and fatigue Clinical symptoms are manifested in varying degrees depending on the age of diagnosis and antibodies to acetylcholine receptors. Facial and oropharyngeal muscles are among the most affected by this disease, thus presenting a lot of difficulties when dental treatment is performed. Since the disease is known to specifically affect the masticatory, facial and oropharyngeal muscles, dental treatment proves very challenging for dentists and patients alike. In order to choose the optimal and less invasive treatment approach and avoid inherent complications, dentists must be acquainted with the clinical features of MG as well as the medications administered in MG patients. Aim: The aim of the present study is to investigate and systematize the clinical presentations of MG in order to choose the most appropriate treatment approach and avoid complications. For this purpose, oral and maxillofacial clinicians must also be acquainted with the main groups of medications for this disease. Materials and Methods : This research relied on Google Scholar and PubMed publications, published in the period 2000–2022. Conclusion: Myasthenia gravis is a serious and rare chronic disease. In order to avoid complications, some of which life-threatening, it is of utmost importance to know its main symptoms as well as applicable medications in dental treatment.
No takes yet. Share an insight, caveat, or question.
Dzhongova et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: